All articles by GlobalData 

  1. Clinical trials continue to develop for growth hormone deficiency, says GlobalData

    Growth hormone deficiency (GHD) is a condition caused by a lack of growth hormone in the human body. The condition…
    Read More…

    18 Nov
  2. Myelodysplastic syndrome cases are under-reported in the US national registry

    Myelodysplastic syndromes (MDS) are a group of rare and diverse hematopoietic malignancies characterised by molecular abnormalities, causing bone marrow failure…
    Read More…

    13 Nov
  3. Oncology: Breast cancer leads Twitter mentions in Q3 2019

    Pharmaceutical Technology lists the top five terms tweeted in oncology in Q3 2019, based on data from GlobalData’s Influencer Platform….
    Read More…

    4 Nov
  4. IDWeek 2019: Climate change poses risks for the spread of infectious diseases

    On 4 October, healthcare practitioners and stakeholders gathered at IDWeek 2019 in Washington DC to discuss issues related to the…
    Read More…

    8 Oct
  5. Novartis’ Zolgensma has Phase I trial planned for 2020 to evaluate SMA infants who present neutralising antibodies, source says

    Novartis (SIX:NOVN) has a Phase I Zolgensma (onasemnogene abeparvovec-xioi) study planned to initiate in 2020 for infants with spinal muscular…
    Read More…

    31 Jul
  6. Stealth’s Phase III elamipretide in mitochondrial myopathy has experts wary while FDA approval debated

    Stealth BioTherapeutics’ elamipretide in primary mitochondrial myopathy (PMM) has experts reserved on Phase III achieving statistical success in its walk…
    Read More…

    17 Jun
  7. Amarin’s Vascepa, AstraZeneca’s Epanova theoretical cardiovascular risk reduction class effect possibly stifled

    Although Amarin’s Vascepa (icosapent ethyl) is likely to lock in US Food and Drug Administration approval and swift uptake in…
    Read More…

    17 Jun
  8. Positive results reported for Eli Lilly’s ultra-rapid insulin

    During the American Diabetes Association’s (ADA’s) 79th Scientific Sessions held in San Francisco, California, US, delegates were able to hear…
    Read More…

    17 Jun
  9. Signs of advancement in metastatic hormone-naive prostate cancer treatment

    Among this year’s biggest developments in prostate cancer was the release of data in patients with metastatic hormone-naive prostate cancer…
    Read More…

    17 Jun
  10. Erleada looks to advance treatment of metastatic hormone-sensitive prostate cancer paradigm

    During this year’s American Society of Clinical Oncology (ASCO 2019) meeting in Chicago, several prostate cancer trials of second-generation hormonal…
    Read More…

    13 Jun
Close
Close
Close

Go Top